+1 (888) 794-0077

COVID-19

Ramp Up: What Drug Developers Need to Know

Ramp Up: What Drug Developers Need to Know

Many drug development companies are prepared to move their programs forward and effectively submit preclinical packages to regulatory bodies. In the challenging business of drug development, disruptions and obstacles are elements that must be part of the conversation...

Alliances for Innovation: Insight from Steve Yang

Alliances for Innovation: Insight from Steve Yang

In the face of a wide-spread pandemic, something extraordinary is happening in the drug development industry – competitors are becoming collaborators and collaborations are accelerating results. WuXi AppTec’s Co-CEO, Head of RSD, Head of WuXi Testing, Steve Yang,...

Tracking Your Molecule: Technology Advancements in the Industry

Tracking Your Molecule: Technology Advancements in the Industry

Molecule tracking via preclinical testing is a significant yet necessary investment for drug developers. The stakes are high, and it's critical to stay apprised of your program's progress from start to finish. You need to monitor how your compound is progressing and...

Partnerships that Prioritize the Customers

Partnerships that Prioritize the Customers

Around the globe, drug developers are trying to understand how the pandemic will impact the progress of their molecule during preclinical testing. Depending on a testing partner's response to the pandemic, your project's status can look drastically different from one...

Selecting a Testing Partner During a Pandemic

Selecting a Testing Partner During a Pandemic

While much of the world continues to cancel events and defer projects in light of the COVID-19 pandemic, drug development often doesn't have the luxury of going on hold. Preclinical drug testing and the submissions that follow can't afford potential delays, which...

Virtual Audits: You Can Now Qualify Testing Sites From Home

Virtual Audits: You Can Now Qualify Testing Sites From Home

Between travel limits and social distancing, in-person visits at testing sites for drug and medical device development are currently not an option. Qualifying testing sites is a standard industry practice, but the resulting restrictions of COVID-19 present new...

The Logistics of Shipping Biological Samples During COVID-19

The Logistics of Shipping Biological Samples During COVID-19

The novel coronavirus (COVID-19) pandemic has thrown many standard procedures out the window, including how companies approach the logistics of shipping biological samples to China. To prevent the introduction and spread of infectious disease, Chinese Customs...

Keeping Your Molecule’s Timeline on Track During COVID-19

Keeping Your Molecule’s Timeline on Track During COVID-19

The unforeseen and drastic effects the COVID-19 pandemic has had on the industry have led to unanticipated challenges, including stricter international shipping regulations, travel restrictions, local lockdowns and more. However, industry leaders are still here to...

Through Partnership We Will Push Forward

Through Partnership We Will Push Forward

As your partner we are taking all the necessary steps to make sure your drug development continues without any disruptions in the process. Moving your molecule forward during COVID-19 doesn’t need to be stressful or difficult. We continue to learn and have found...